注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Aclaris Therapeutics Inc是一家臨床階段的生物製藥公司。該公司專註於開發免疫炎癥性疾病的候選藥物。該公司專註於利用其在藥物發現和開發以及激酶抑製方面的經驗來開發小分子療法,以幫助人們改善免疫炎癥狀況。其候選藥物包括Zunsemetinib (ATI-450)、ATI-1777和ATI-2138。該公司的ATI-450是一種研究用的口服、小分子選擇性MK2抑製劑化合物,用於治療類風濕性關節炎。其ATI-1777是一種研究性局部用JAK 1/3抑製劑化合物,用於治療特應性皮炎。該公司還致力於開發ATI-2138,一種研究性口服抑製劑化合物,是T細胞介導的自身免疫性疾病的潛在治療方法。該公司還在開發口服腸道偏向JAK抑製劑,用來作為炎癥性腸病的潛在治療方法。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Neal S. Walker | 54 | 2012 | Co-Founder, President, Chairman & Interim CEO |
Marco Colonna | - | 2020 | Member of the Scientific Advisory Board |
Michael E. Weinblatt | - | 2020 | Member of the Scientific Advisory Board |
Philip J. Mease | - | 2021 | Member of Scientific Advisory Board |
Stanley B. Cohen | - | 2020 | Member of the Scientific Advisory Board |
James G. Krueger | - | 2020 | Member of the Scientific Advisory Board |
Christopher P. Molineaux | 58 | 2014 | Lead Independent Director |
Andrew Newman Schiff | 59 | 2017 | Independent Director |
Guy F. Webster | - | - | Member of Advisory Board |
Mark Bradshaw | 71 | - | Member of Advisory Board |
Leslie Baumann | - | - | Member of Advisory Board |
Pearl E. Grimes | - | - | Member of Advisory Board |
Klaus PJ Theobald | 68 | - | Member of Advisory Board |
Kenneth Beer | - | - | Member of Advisory Board |
William D. Humphries | 58 | 2016 | Independent Director |
Anand Mehra | 48 | 2014 | Independent Director |
James J. Leyden | 83 | - | Member of Advisory Board |
Bryan M. Reasons | 57 | 2018 | Independent Director |
Andrew L. Ondo | - | - | Member of Advisory Board |
Maxine Gowen | 66 | 2019 | Independent Director |
Andrew Kenneth Williams Powell | 66 | 2017 | Independent Director |
Vincent J. Milano | 60 | 2020 | Independent Director |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核